The aim of the present study was to compare the clinical, radiological and histomorphometrical outcome of simultaneous implant placement following augmentation of atrophic maxillary sinuses using ...
Maxillary sinus augmentation encompasses surgical methods designed to increase bone volume in the posterior maxilla to support dental implants. Two principal approaches are employed: the lateral ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a ...
Lower health care utilization was shown in patients with chronic rhinosinusitis, with and without nasal polyps, who had steroid-eluting implants vs those who did not in the 18 months following ...
Intersect ENT is launching its Sinuva Sinus Implant, a new approach to treating nasal polyp disease in adult patients who have had previous sinus surgery. The Menlo Park, CA-based company said nearly ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a ...
Placed during a routine physician office visit, SINUVA expands in the sinus cavity and delivers an anti-inflammatory steroid directly to the site of polyp disease for up to 90 days. SINUVA was ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...
Intersect ENT showed it has another device to add to its line of sinus implants, touting positive data from a pilot study of its new steroid delivery implant to treat chronic sinusitis. The ...
Steroid-eluting implants inserted during or after sinus surgery may benefit patients with chronic sinusitis with or without nasal polyps, including those who can't tolerate oral steroids, a consensus ...
Recent med tech IPO candidate Intersect ENT ($XENT) has reported the results of three studies for its chronic sinusitis implants at the American Rhinologic Society ...
Intersect ENT received CMS approval of a revised coding application for its Propel sinus implant, according to a Jan. 19 news release. Propel previously shared a billing code with Intersect ENT’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results